Beyond GLP-1s: Building a resilient cash-pay formulary

The current demand for GLP-1s has been a significant driver for compounding pharmacies, but the long-term question remains: What does your revenue mix look like once the market starts to saturate?

As more players enter the space, margins naturally compress. The pharmacies positioned for 2026 aren't just fulfilling GLP-1 orders; they are building comprehensive wellness programs that offer more value per patient.

We have put together a report on 12 High-Margin Peptide Formulations that sit alongside GLP-1 therapy. These are compliant, high-utility compounds that help you diversify your clinical offerings.

The report covers:

• Clinical utility: 12 compounds with clear regulatory pathways.

• Protocol integration: How to bundle for metabolic, cognitive, and aesthetic health.

• Business modeling: Shifting from single-category reliance to a multi-stream model.

You can download the full breakdown here: https://503pharma.com/high-profit-peptides

Thank you!

P.S. If this was helpful, forward it to a colleague. We're building a community that learns together and lifts the whole industry.